Adipocytokines mark insulin sensitivity in euthyroid Hashimoto's patients.
The relationship between inflammation, Hashimoto's thyroiditis (HT) and insulin resistance is still controversial. In this regard, a pretty complete evaluation of adipocytokines levels in patients with HT has not been performed so far. We assessed retinol binding protein-4 (RBP4), adipocyte-fatty acid binding protein (A-FABP), neutrophil gelatinase-associated lipocalin (NGAL) and tumor necrosis factor-α (TNFα) levels in 93 euthyroid HT patients and 51 healthy controls (CTL), also evaluating the possible correlation between adipocytokines levels and markers of insulin resistance. No significant differences between HT patients and CTL in fasting plasma glucose and insulin levels, and HOMA index were observed. HT patients had significantly higher RBP4, NGAL and A-FABP levels than CTL, while TNFα levels did not differ between the two groups. In HT patients, RBP4 was significantly related with fT3 and fT4 levels, while A-FABP with fT4 only. Moreover, in HT patients, either RBP4 or A-FABP was directly associated with plasma insulin and HOMA index. Circulating levels of these adipocytokines were not influenced by the presence of antithyroid peroxidase or antithyroglobulin autoantibodies or only one of them, neither by autoantibodies titer. In conclusion, euthyroid HT patients are characterized by a peculiar inflammatory response of the adipose tissue, apparently related to an early reduction in insulin sensitivity and to serum thyroid hormone levels, although within the normal range. These results suggest that HT patients with high RBP4 and A-FABP levels might deserve a particular attention, being potentially more exposed to develop insulin resistance and increased cardiovascular risk.
Department of Internal Medicine, University of Pisa, Italy. anna.solini@med.unipi.it
Anna
A
Solini
Angela
A
Dardano
Eleonora
E
Santini
Antonio
A
Polini
Fabio
F
Monzani
D000209:Acute-Phase Proteins; D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D016022:Case-Control Studies; D050556:Fatty Acid-Binding Proteins / Q000097:blood; D005260:Female; D050031:Hashimoto Disease / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011518:Proto-Oncogene Proteins / Q000097:blood; D054839:Retinol-Binding Proteins, Plasma / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D000209:Acute-Phase Proteins; D054392:Adipokines; D001786:Blood Glucose; C493410:FABP4 protein, human; D050556:Fatty Acid-Binding Proteins; D007328:Insulin; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D014409:Tumor Necrosis Factor-alpha